European approval of nivolumab plus ipilimumab for first-line treatment of metastatic non-small cell lung cancer

Approval was based on results from the phase III CheckMate-9LA trial, where nivolumab plus ipilimumab, in combination with chemotherapy, reduced risk of death by 31% vs chemotherapy alone and increased median progression-free survival (6.8 vs 5.0 months).

Source:

PharmaTimes